NEW YORK, July 22, 2015 /PRNewswire/ --
ACI Association has initiated research coverage on Amyris, Inc. (NASDAQ: AMRS). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.
Today, membership is open to readers on a complementary basis at the following URL: http://www.aciassociation.com/?c=AMRS
Highlights from our AMRS Report include:
- First Agreement in Food Sector - On July 16, 2015, Amyris, Inc. announced that it has entered into a multi-year, multi-million-dollar collaboration agreement with a global food ingredients supplier. This partnership represents its first collaboration in the growing food ingredients sector. Following the announcement, the Company's shares soared 11.73% to close the session at $2.00.
- Details of the Agreement - Under the agreement, the partner, whose name was not disclosed by the Company, will provide funding for the development program, which will be executed by Amyris. Additionally, the agreement includes a long-term value share provision in regard to future end-market product sales by the partner.
- Management Statements - Commenting on the partnership, John Melo, President and CEO of Amyris, stated, "We're excited with the continued momentum in executing our plan with growing our collaboration partnerships. This collaboration adds to our current portfolio of collaboration partners and our growing portfolio of over 20 products under agreement with more than 10 partners." Melo added, "We are on track to introduce three new commercial products this year for our partners as a result of our earlier collaborations. Collaborations continue to fund our direct R&D costs and provide strong product revenue growth."
- Other Recent Agreements - On June 25, 2015, the Company had announced an exclusive re-seller agreement for its Neossance® cosmetic ingredients with Dinaco Importação Comércio S.A. - a Brazilian company specializing in cosmetic product distribution for the Brazilian market. As part of the agreement, Dinaco, which distributes products and ingredients for many of the world's most important cosmetics and other manufacturers, would purchase and exclusively re-sell Amyris's Neossance® Squalane and Neossance® Hemisqualane products throughout Brazil. Previously, on June 9, 2015, the Company announced the signing of a Letter of Intent (LOI) to establish an agreement for Amyris to supply a key starting material for an active pharmaceutical ingredient to Mumbai, India-based Ipca Laboratories Ltd.
To find out how this influences our rating on Amyris, Inc., read the full report in its entirely here: http://www.aciassociation.com/?c=AMRS
About ACI Association:
Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.
ACI Association, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.aciassociation.com/.
ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) aciassociation.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.